Citations

Clear

4610 citation(s) found for "Hu, Brian".

An automated plasma‐based proteotyping immunoassay for APOE ε4 zygosity classification in Alzheimer's disease
Levin, Scott , Engel, Brian, Carlson, Corey M., Hinson, Jeremiah, Holland, Mark D. , Figdore, Dan, Tiers, Laurent, Bhatt, Kinal , Schlichtmann, Ben, Hoffmann, Katie, Bae, Ye Eun, Szabo, Miklos, Um, Yoo Hyun , Algeciras-Schimnich, Alicia, Hinson, Jeremiah S. , Figdore, Daniel J. , Lim, Hyun Kook , Schlichtmann, Benjamin W. , Lehmann, Sylvain , Algeciras‐Schimnich, Alicia

Mayo Clinic

Alzheimer's & Dementia | March 8, 2026 | Volume: 22 | Issue: 3 | Pages: No page available

10.1002/alz.71143 | PMID 41789706 Get It

Abstract INTRODUCTION Determining apolipoprotein E ( APOE ) ε4 allele status, a key genetic risk factor for Alzheimer's disease (AD), requires molecular genotyping infrastructure not widely accessible beyond specialized centers. METHODS A fully automated high‐throughput apoE E4 proteotyping immunoassay was evaluated for clinical performance (460 participants across three cohorts) and analytical validity. Concordance with polymerase chain reaction (PCR)‐based genotyping and measures of analytical validity were reported. RESULTS The apoE E4 immunoassay demonstrated 99.6% (95% confidence interval [CI]: 98.4% to 99.9%) concordance with PCR‐based APOE ε4 genotype results across the pooled clinical cohort; 100.0% (95% CI: 97.1% to 100.0%) in those with AD ( N = 127) and 99.4% (95% CI: 97.8% to 99.8%) in those without AD (333). The assay met analytical validity criteria for E4 isoform specificity, interference, precision, and stability. DISCUSSION The apoE E4 immunoassay demonstrated high concordance with PCR‐based genotyping and robust analytical validity, offering an accessible alternative for APOE ε4 zygosity assessment. Highlights A novel high‐throughput plasma‐based proteotyping immunoassay for APOE ε4 zygosity classification was developed and evaluated for clinical performance and analytical validity. The apoE E4 immunoassay demonstrated high concordance (99.6%) with PCR‐based APOE ε4 genotyping across a diverse international cohort, and a robust analytical profile. An apoE E4 immunoassay may offer a more cost‐effective and accessible alternative to DNA genotyping approaches currently used for AD risk evaluation and anti‐amyloid treatment decisions.
The CARE framework for AI dataset documentation in clinical laboratories: a comprehensive checklist and data lineage methodology
Garcia, Christopher A., Reed, Katelyn A. , Lantz, Eric, Day, Patrick L. , Stadler, Brian C, Zarella, Mark D. , Hart, Steven N. , Han, Wenchao, Wahsh, Ezzaddin Al, Novak, Debra, McClintock, David S. , Day, Patrick , Tavolara, Thomas E, Al Wahsh, Ezzaddin, Novak, Debra A, McClintock, David S , Hart, Steven N , Lantz, Eric, Han, Wenchao, Tavolara, Thomas Erol , Wahsh, EzzAddin Al, Novak, Debra A

Mayo Clinic

American Journal of Clinical Pathology | March 7, 2026 | Volume: 165 | Issue: 5 | Pages: No page available

10.1093/ajcp/aqag029 | PMID 42114029 Get It

Abstract Objectives Traditional laboratory regulatory frameworks provide robust guidance for conventional clinical testing but lack requirements for data documentation for artificial intelligence and machine learning (AI/ML) solutions. This gap creates significant risks since AI solutions directly inherit patterns, biases, and limitations from their training data. Here, we describe the development and implementation of a comprehensive data documentation checklist with accompanying data lineage for use within an AI lifecycle framework for clinical laboratories. Methods Building on the previously established Clinical AI Readiness Evaluator (CARE) framework, we developed a comprehensive data checklist and data lineage methodology through a multiphase process, including (1) comprehensive review of existing AI/ML data documentation frameworks, (2) focused meetings with 3 institutional AI operations teams, and (3) 3 rounds of iterative refinement by our multidisciplinary team. The checklist’s effectiveness was then assessed using 3 diverse AI/ML projects moving through the CARE framework. Results The CARE Data Checklist and Data Lineage provide a structured approach to documenting critical aspects of datasets used in AI/ML projects, including data composition, demographics, collection methods, labeling processes, usage constraints, maintenance requirements, and a data readiness assessment. The checklist addresses unique data-centric challenges of AI/ML applications, facilitating transparency, reproducibility, and regulatory compliance. Conclusions The CARE Data Checklist and Data Lineage serve as both a technical guide and a communication tool bridging gaps between technical and clinical stakeholders. By working on these documents early in the AI lifecycle, laboratories can anticipate and address data-related challenges, ultimately saving time, optimizing resources, and improving the reliability of AI-augmented laboratory solutions.
Comparing the Efficacy Between ChatGPT 5, Grok 3, and Claude 4.5 Sonnet in Analyzing Orthopedic Trauma-Related Imaging
Holmstrom, Joshua Aaron , Braithwaite, Collin , Alhankawi, Ahmad R. , Moore, M. Lane, Patel, Karan A. , Miller, Brian H., Moore, M. Lane , Alhankawi, Ahmad R. , Holmstrom, Joshua A , Braithwaite, Collin L , Moore, M Lane , Patel, Karan

Mayo Clinic

Journal of Orthopaedic Trauma | March 5, 2026 | Volume: 40 | Issue: 7 | Pages: 360-365

10.1097/bot.0000000000003166 | PMID 41785426 Get It

OBJECTIVES: To evaluate and compare the ability of three popular open-source artificial intelligence platforms to diagnose common trauma-related fractures using radiologic imaging. METHODS: Design: Retrospective diagnostic performance comparison study. Setting: Publicly accessible online radiologic imaging databases. Patient Selection Criteria: Five common orthopedic trauma fractures were assessed: ankle, tibial plateau, intertrochanteric, femoral neck, and humerus. Radiographs and computed tomography (CT) images were collected. Images were randomly selected from confirmed diagnoses on Radiopaedia.org. Outcome Measures and Comparisons: ChatGPT 5, Grok 3, and Claude 4.5 Sonnet were queried with each image. Diagnostic accuracy, sensitivity, specificity, positive and negative predictive values, and performance by modality (X-ray vs. CT) were assessed. The reference standard was the expert-verified diagnosis provided by Radiopaedia.org, limited to cases labeled with a “diagnosis certain” tag. RESULTS: Each model was provided with 30 radiographs and 20 CT images whenever possible. ChatGPT 5, Grok 3, and Claude 4.5 Sonnet accurately diagnosed diseased images in 26.8%, 18.8%, and 22.4% of cases, respectively. By fracture type, ChatGPT 5 demonstrated the highest correct classification rates for ankle (10%), femoral neck (38%), humerus (40%), and tibial plateau (44%) fractures. Grok 3 demonstrated the highest correct classification rate for intertrochanteric fractures (6%). Overall sensitivities were 0.267, 0.187, and 0.223 for ChatGPT 5, Grok 3, and Claude 4.5 Sonnet, respectively. ChatGPT 5 and Grok 3 outperformed Claude 4.5 Sonnet (both P < 0.001). No modality-based performance differences were observed for any model. CONCLUSIONS: Among the publicly available large language models evaluated for radiologic interpretation of orthopedic trauma imaging, ChatGPT 5 demonstrated the highest overall diagnostic accuracy, followed by Claude 4.5 Sonnet and Grok 3. Despite relative variation between the models, overall diagnostic accuracy for fracture detection was low across all platforms (<27%). In their baseline forms, these publicly accessible large language models are not recommended for radiologic imaging interpretation. LEVEL OF EVIDENCE: Diagnostic Level III. See Instructions for Authors for a complete description of levels of evidence.
Integrative screening identifies functional variants and VNTRs underlying GWAS signals at the 5p15.33 multi-cancer susceptibility locus
O’Brien, Aidan , Kong, Hyunkyung, Patel, Harsh , Ho, Michelle , Patel, Minal, Zhong, Jun , Xu, Mai, Papenberg, Brenen W. , Connelly, Katelyn E. , Collins, Irene , Hennessey, Rebecca C. , Thakur, Rohit , Sowards, Hayley , Funderburk, Karen, Luong, Thong Minh, Florez-Vargas, Oscar , Myers, Timothy , Jermusyk, Ashley , Gorman, Bryan, Das, Sudipto, (PanScan/PanC4), The Pancreatic Cancer Cohort and Case-Control Consortia, Lan, Qing, Rothman, Nathaniel , McKay, James , Hung, R., Iles, Mark M. , Landi, Maria Teresa , Stolzenberg-Solomon, Rachael Z, Wolpin, Brian M. , Hassan, Manal M. , Antwi, Samuel O. , Lindström, Sara , Stern, Marc-Henri, Andrésson, Þorkell , Shi, Jianxin , Choi, Jiyeon, Brown, Kevin M, Rabe, Kari G. , Patel, Minal B , Hennessey, Rebecca , Luong, Thong , Jones, Kristine , Das, Sudipto , McKay, James , Hung, Rayjean J , Amos, Christopher I , Iles, Mark M , Koutros, Stella , Landi, Maria T , Law, Matthew H , Hassan, Manal M , Klein, Alison P , Orr, Nick , Chanock, Stephen Jacob , Lindstrom, Sara , Hoskins, Jason W , Shi, Jianxin , Prokunina-Olsson, Ludmila , Choi, Jiyeon , Brown, Kevin M , Amundadottir, Laufey , Chaffee, Kari G. , Antwi, Samuel O , Zhong, Jun , Luo, Wen , Lan, Qing , Rothman, Nathaniel , Amos, Christopher I. , Koutros, Stella , Law, Matthew H. , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Orr, Nick , Hoskins, Jason W. , Stern, Marc‐Henri , Choi, Jiyeon , Ámundadóttir, Laufey T.

Mayo Clinic

No container title available | March 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.03.26347427 | PMID 41867231 Get It

Abstract Chromosome 5p15.33 harbors several independent association signals which demonstrate antagonistic pleiotropy across cancer types, with causal mechanisms largely unresolved. To identify functional variants and enhancer elements at this locus, we performed statistical fine-mapping followed by massively parallel reporter assays (MPRA) and proliferation based CRISPRi screens. This approach identified eight multi-cancer functional variants (MCFVs) across three GWAS signals. Targeting rs421629 (part of the CLPTM1L signal marked by rs465498) with CRISPRi revealed opposing effects on TERT expression in pancreatic versus lung cancer cells, consistent with the antagonistic pleiotropy observed for this signal. Furthermore, CRISPRi nominated an intronic CLPTM1L variable number tandem repeat (VNTR) as a potent enhancer. Long-read sequencing established VNTR polymorphisms as potential causal variants for the rs465498 signal. We showed that Hippo-pathway transcription factors mediate VNTR enhancer activity in lung and pancreatic cancer cells. Together, these findings indicate that cancer susceptibility at 5p15.33 may be mediated by both SNPs and VNTRs and provide an integrated framework for resolving complex pleiotropic loci.
Prognostic factors and progression biomarkers in AL amyloidosis: mapping current knowledge and critical gaps
Brailovsky, Yevgeniy, Hanna, Mazen, Witteles, Ronald, Vaishnav, Joban , Griffin, Jan Marie, Garcia-Pavia, Pablo, Wolinsky, David G. , Karam, Chafic, Lachmann, Helen J, Gertz, Morie A., Bampatsias, Dimitrios, Hsu, Kristen , Johnson, Phaedra Theodora, Zigterman, Jamie, Kazemzadeh, Ana Carolina, Maurer, Mathew S., Wechalekar, Ashutosh D., Karam, Chafic , Chakraborty, Rajshekhar , Brailovsky, Yevgeniy , Garcia-Pavia, Pablo , Wolinsky, David , Karam, Chafic , Lachmann, Helen , Hsu, Kristen , Johnson, Phaedra , Zigterman, Jamie , Chakraborty, Rajshekhar , Brailovsky, Yevgeniy , Hanna, Mazen , Witteles, Ronald , Hoffman, James Edward, Griffin, Jan M. , Lachmann, Helen J. , Gertz, Morie A. , Boursiquot, Brian C. , Bampatsias, Dimitrios, Maurer, Mathew S , Wechalekar, Ashutosh D.

Mayo Clinic

Blood | March 4, 2026 | Volume: 147 | Issue: 21 | Pages: 2448-2462

10.1182/blood.2025031651 | PMID 41779722 Get It

Abstract The therapeutic landscape for systemic immunoglobulin light chain (AL) amyloidosis has been revolutionized by daratumumab-based regimens, achieving 76% 5-year overall survival in the landmark ANDROMEDA trial. However, the current prognostic models were developed using patient populations treated with now-suboptimal therapies, creating a critical gap between risk stratification models and contemporary outcomes. This comprehensive review analyzes prognostic factors and progression biomarkers in AL, categorizing them into disease-specific (clone-related and organ-related) and patient-specific factors. Notably, traditional baseline biomarkers including difference between involved and uninvolved free light chains and bone marrow plasma cell burden are losing prognostic significance with effective clone-directed therapies. Emerging approaches show promise, including dynamic markers such as minimal residual disease by free light chain mass spectrometry, cardiac imaging parameters such as global longitudinal strain, and functional measures. There is an urgent need for validation studies and prognostic model refinement to identify patients at high risk who may benefit from interventions beyond anti–plasma cell therapy.
Society of Critical Care Medicine Guidelines for the Administration of Neuromuscular Blockade in Adults With Acute Respiratory Distress Syndrome
Erstad, Brian L. , Cobas, Miguel Angel, Qadir, Nida , Alshamsi, Fayez, Sharif, Sameer, Devine, Elizabeth M., Einav, Sharon, Elmer, Jennifer, Fort, Alexander C., Harrod, Christopher G., Lamb, Keith D., Mehta, S., Mitchell, Dannette A., Paruk, Fathima, Sacha, Gretchen, Schell‐Chaple, Hildy , Sinha, Sharmili , Smith, S. Ray , TOPELİ, Arzu, Alshamsi, Fayez , Qadir, Nida , Sharif, Sameer , Devine, Scott , Heavner, Mojdeh S. , Lamb, Keith, Mehta, Sangeeta , Piraino, Thomas , Sacha, Gretchen , Smith, Susan E., Topeli, Arzu , Sarwal, Aarti

Mayo Clinic

Critical Care Medicine | March 3, 2026 | Volume: 54 | Issue: 3 | Pages: 634-643

10.1097/ccm.0000000000007002 | PMID 41773929 Get It

Rationale: Neuromuscular blocking agents (NMBAs) show potential benefits on mortality and other complications of acute respiratory distress syndrome (ARDS) in adult patients. Evidence-based decisions and processes ensure appropriate use of neuromuscular blockade in adult patients with ARDS. Objectives: The objective of these guidelines was to develop evidence-based recommendations for the administration of NMBAs in critically ill adult patients with ARDS. Design: The American College of Critical Care Medicine Board convened a 21-member multidisciplinary panel of experts in critical care medicine, nursing, respiratory therapy, pharmacology, surgery, neurology, and anesthesiology. The panel included two expert methodologists specialized in developing evidence-based recommendations in alignment with the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. Conflict-of-interest policies were strictly followed during all phases of guidelines development including task force selection and voting. Methods: The panel members identified and formulated five Population, Intervention, Comparison, and Outcome questions. We conducted a systematic review for each question to identify the best available evidence, statistically analyzed the evidence, and assessed the certainty of the evidence using the GRADE methodology. We used the GRADE evidence-to-decision framework to formulate the recommendations. Results: The panel generated two conditional recommendations. One recommendation is to use NMBAs in adults with ARDS with Pa o 2 /F io 2 less than 150. For the other recommendations, there was equipoise in the recommendation for and against using titratable vs. fixed-dose NMBA dosing, a monitoring-based strategy for assessing depth of sedation and analgesia in adults with ARDS before initiating or while receiving neuromuscular blockade, and administration of NMBAs for patients who are proned, due to overall lack of evidence in critically ill patients and due to considerations of patient safety and experience concerns. Conclusions: These guidelines provide additional perspectives on the use of NMBA in patients with ARDS, recognizing that institutional and patient-specific considerations must help to guide the decision-making process.
Quality of life and care experiences in a US multi-institutional neuroendocrine tumor cohort
O’Rorke, Michael A, DeCook, Rhonda, McDowell, Bradley D. , Gryzlak, Brian , Rudzianski, Nicholas J, Serrano, Kimberly , Wehrheim, Abigayle M., Grewal, Udhayvir Singh , Halfdanarson, Thorvardur R, Gamblin, T Clark, Cowell, Lindsay G, Else, Tobias , Chandaka, Sravani , He, Fiona , Geller, David, Ramirez, Robert A, Lancaster, W. M., Mailman, Josh A, Moran, Heather, Wahmann, Maryann, Gellerman, Elyse, Chrischilles, E., Investigators, The NET-PRO Study, Chamberlain, Alanna M, Cerda, Vanessa, Early, Carol, Hamilton, Harley C, Indrees, Kamran, Lewis-Hughes, A., O’Dell, Angela L, Roller, Lance, Taylor, Bradley W, Tepper, Mia S, Wahmann, Maryann, West, Kristin M, Zamba, Gideon K D, O’Rorke, Michael A. , Xu, Tao , McDowell, Bradley D , Gryzlak, Brian M , Rudzianski, Nicholas J , Serrano, Kimberly C , Grewal, Udhayvir S , Dillon, Joseph S , Halfdanarson, Thorvardur R , Else, Tobias , Soares, Heloisa P , Sukrithan, Vineeth , Sanoff, Hanna , He, Fiona C , Ramirez, Robert A , Liu, Mei , Mailman, Josh , Moran, Heather , Wahmann, Maryann , Gellerman, Elyse , Chrischilles, Elizabeth A , Xu, Tao , Chandrasekharan, Chandrikha , Dillon, Joseph S. , Hálfdánarson, Þorvarður R. , Gamblin, T. Clark , Cowell, PhD Lindsay G., Soares, Heloisa P. , Sukrithan, Vineeth , Sanoff, Hanna K. , Liu, Mei , Lancaster, William, Mailman, Josh , Chamberlain, Alanna M. , Hourcade, Juan Pablo , Kazmi, Syed Mohammad Ali , Lancaster, William, Ramnaraign, Brian Hemendra , Taylor, Bradley , West, Kristin M, Zamba, Gideon K D

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 3, 2026 | Volume: 118 | Issue: 8 | Pages: 1403-1415

10.1093/jnci/djag069 | PMID 41808486 Get It

Abstract Background Neuroendocrine tumors (NETs) are rare, heterogeneous neoplasms associated with prolonged survival and substantial symptom burden. However, patient-reported outcomes across NET subtypes remain poorly characterized, particularly in real-world settings. This study describes baseline health-related quality of life (HRQoL) and care experiences among patients with gastroenteropancreatic and lung NETs, examining differences by tumor site and time since diagnosis. Methods The Neuroendocrine Tumors–Patient Reported Outcomes study is a prospective, multi-institutional US cohort of adults (aged 18 years and older) with incident small intestinal, pancreatic, gastroenteropancreatic, or lung NETs diagnosed from January 2018 through September 2024, identified via a validated electronic medical record–based computable phenotype. Baseline surveys assessed HRQoL, symptoms, care experiences, and clinical characteristics using validated instruments. Descriptive statistics and standardized mean differences compared responses by NET site and time since diagnosis. Results Among 2367 participants (mean age = 57.8 years; 57.3% female), 1974 had gastroenteropancreatic NETs (659 small intestinal NET, 555 pancreatic NET) and 393 had lung NETs. Fatigue (mean = 33.0), insomnia (mean = 32.5), and diarrhea (mean = 25.7) were the most burdensome symptoms. Lung NET patients reported worse dyspnea (standardized mean difference = 0.58, P &lt; .001) and lower physical, role, and global QoL scores than those with gastroenteropancreatic NETs, while pancreatic NET patients reported better functioning. Diarrhea worsened over time, especially in small intestinal NETs. Most rated care highly (75.3%) but cited concerns about treatment side effects (80.4%), costs (60.7%), and travel burden (58.8%). Conclusions This large US cohort reveals persistent symptom burden and HRQoL variation by tumor site and disease duration, underscoring the need for longitudinal HRQoL assessment in NET care.